ANNEX I

Information for transmission of information about detected signals

MINIMAL DATA THAT SHOULD BE FILLED IN EVERY CASE

1. Identification:

- Type of message categories: Rapid Alert/Non-urgent Message
- Reference
- From:
- To:
- Date:

2. Drug(s)

- Brandname(s):
- Active substance(s): (INN, DCI)
- Pharmaceutical form and dosage (if appropriate):
- Marketing authorisation holder(s)
- Manufacturer (if essential)

3. Reason for Alert

- Source of information: Spontaneous reports/Post-Marketing Study/Clinical Trial/Pre-clinical Study
- Summarised evidence relevant to alert

4. Actions

- Action(s) proposed
- Action(s) taken (steps taken to collect more information at a national level and temporary steps taken to limit risks)

5. Information exchange

- Information required

ANNEX II

Pharmacovigilance Assessment Report

FORMAT AND CONTENT

I. Introduction

This section should clarify why the assessment has been undertaken.

II. Assessment of risks

This section will be specifically devoted to the safety concern under evaluation. It should encompass all relevant sources of information, including spontaneous reports, published literature, studies (pre-marketing clinical trials, postmarketing studies, epidemiological studies and intensive monitoring data), other data, e.g. mortality data to:

a) characterise the problem (nature, severity, outcome);

b) assess causal association;

c) estimate frequency and comparative frequency, where possible;

d) provide evidence of risk factors.

III. Assessment of benefits

It should take into account the following, where known:

a) the nature of the illnesses for which the medicine is indicated (e.g. fatal, life-threatening, disabling, self-limiting, etc.);

b) absolute efficacy, as judged by placebo-controlled clinical trials;

c) relative efficacy, as judged by studies comparing efficacy with that of appropriate alternative treatment(s);

d) the characteristics of the population exposed to the medicine (e.g. elderly and hospitalised, young and healthy, etc.).

IV. Overall risk-benefit evaluation

This section includes:

a) an overall benefit/risk analysis in the context of the safety problem under assessment and relevant comparative safety with other drugs in the same class or for the same therapeutic indication;

b) discussion of the options for improving the risk-benefit ratio;

c) recommended options for responding to the safety issue.

ANNEX III

TEMPLATE FOR

FINAL REPORT FOLLOWING THE RAPID ALERT

OF

< ACTIVE INGREDIENT >

Status: < for INFORMATION >

TABLE OF CONTENTS

ABSTRACT OF THE ALERT PROCEDURE AND PRODUCT PROFILE (ON ONE PAGE)

Alerting Member State

Problem/Subject

Drug

- INN name
- Brand name(s)
- Strength(s)
- Pharmaceutical form(s)
- Route of administration
- Therapeutic Classification (ATC-code)

Indications

Reason for Alert

Proposed action or action taken

BACKGROUND INFORMATION ON THE PROCEDURE

Starting Point

- When
- By whom
- The concern
- The drug
- The source of the concern

  (e.g. case reports from spontaneous reporting, epidemiological study)

Referral to the National Advisory Board

- When
- Which matter
- Followed national inquiries (e.g. Stufenplan)

The proceedings of the National inquires

- When
- On which problem
- On which substance
- Involvement of the marketing authorisation holders

  ⇒ Time frame

  ⇒ Explanations of the MAH(s) in writing/orally

Alerting the Member States

- When, by (e.g. Fax, e-mail)
- On which problem
- On which INN-name
- Call for (e.g.)

  ⇒ case reports

  ⇒ details of legal status in the Member State

  ⇒ information on supply and use
- Answers received from

Involvement of the Pharmacovigilance Working Party

- The subject was

  ⇒ presented by, when

  ⇒ discussed on, when
- Additional explanations of the MAH(s) were given

⇒ when
⇒ in writing (expert report)
⇒ orally

- Assessment reports were prepared
  ⇒ by , when
  ⇒ reviewed, updated, finalised

- A report of the Pharmacovigilance Working party was given
  ⇒ when
  ⇒ to (e.g. the CPMP, the MAH, others)

SCIENTIFIC DISCUSSION

- Overview of the safety concerns
  ⇒ Adverse drug reactions
  ⇒ Risk of correct treatment (e.g. defined populations at risk)
  ⇒ Risk of inappropriate treatment (if applicable)
- Overview of benefit
  ⇒ Efficacy of drug
  ⇒ Effectiveness of drug treatment
- Overall risk - benefit assessment
  ⇒ of drug under consideration
  ⇒ place on the market
  ⇒ compared to alternative treatment(s)

PROPOSED ACTIONS / ACTIONS TAKEN

- Variation of the marketing authorisation
  ⇒ Proposed conditions of supply and use
  ⇒ Proposed warnings of health professionals and/or patients (e.g. Dear Doctor Letter)
  ⇒ Proposed changes of the SPC or parts of it
  ⇒ Provision of further evaluation for the MAH(s)

- Suspension of the marketing authorisation
  ⇒ from, to
  ⇒ with obligation to fulfil in between
- Withdrawal of the marketing authorisation
  ⇒ in force from
  ⇒ recall of products on the market is included
- Referral to CPMP
  ⇒ Community interest involved

ANNEXES

(Annexes if appropriate,)

Form A

Sign of the competent authority of the Member State

RAPID ALERT IN **PHARMACOVIGILANCE** **URGENT**		
Reference	No of pages No of annexes	Date
FROM/EXPEDITEUR		
TO: ALL MEMBER STATES THE COMMISSION EMEA CHAIR-CPMP		

SUBJECT / OBJET:

Brandname:

Substance (INN, DCI):

Formulation and dosage (if appropriate):

Manufacturer (if essential):

REASONS FOR ALERT / RAISON DE L'ALERTE

Keywords

REASONS OF ALERT / RAISON DE L'ALERTE:
(Text)
PROPOSED ACTION AND ACTION TAKEN / MESURES ENVISAGEES ET MESURES PRISES:
(Text)
INFORMATION REQUESTED / INFORMATION DEMANDEE AUX DESTINATAIRES:
(Text)
ADDITIONAL INFORMATION / INFORMATION ADDITIONELLE
(Text)
Signature / Signature:

Form B

Sign of the competent authority of the Member State

ANSWER TO RAPID ALERT IN PHARMACOVIGILANCE		
Reference	No of pages No of annexes	Date
FROM/EXPEDITEUR		
TO: [THE ORIGINATING MEMBER STATE] EMEA OTHER RECIPIENTS		

SUBJECT / OBJET:

Brandname-

Substance (INN, DCI):

Formulation and dosage (if appropriate):

Marketing authorisation holder(s):

Manufacturer (if essential):

ANSWER TO RAPID ALERT:
(Text)
PROPOSED ACTION AND ACTION TAKEN / MESURES ENVISAGEES ET MESURES PRISES:
(Text)
ADDITIONAL INFORMATION / INFORMATION ADDITIONELLE
(Text)
Signature / Signature: